Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 5/20 | 0.53 |
| ▸ | PAM | P19021 | 2/20 | 0.52 |
| ▸ | CES2 | O00748 | 3/20 | 0.50 |
| ▸ | CES1 | P23141 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | PPARG | P37231 | 6/20 | 0.48 |
| ▸ | PPARD | Q03181 | 6/20 | 0.48 |
| ▸ | PPARA | Q07869 | 6/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.48 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | TLR2 | O60603 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | FABP4 | P15090 | 2/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.48 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.48 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6163945 | 1.00 | DGKA (0.57) | DGKALMNATSHRPAMCES2 | |
| SCHEMBL5517470 | 1.00 | DGKA (0.57) | DGKALMNATSHRPAMCES2 | |
| SCHEMBL6163541 | 1.00 | DGKA (0.57) | DGKALMNATSHRPAMCES2 | |
| SCHEMBL698428 | 1.00 | DGKA (0.57) | DGKALMNATSHRPAMCES2 | |
| SCHEMBL8332466 | 1.00 | DGKA (0.57) | DGKALMNATSHRPAMCES2 | |
| SCHEMBL8896528 | 1.00 | DGKA (0.57) | DGKALMNATSHRPAMCES2 | |
| SCHEMBL2892144 | 1.00 | DGKA (0.57) | DGKALMNATSHRPAMCES2 | |
| SCHEMBL5508667 | 1.00 | DGKA (0.57) | DGKALMNATSHRPAMCES2 | |
| SCHEMBL2254535 | 1.00 | DGKA (0.57) | DGKALMNATSHRPAMCES2 | |
| SCHEMBL5512722 | 1.00 | DGKA (0.57) | DGKALMNATSHRPAMCES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7994152-B2 | Method of treating a cancer by administering A 2′,5′-oligoadenylate analog | SANKYO COMPANY, LIMITED (JP) | 2011-08-09 | — | — | US | disclosed |
| US-20100035976-A1 | Method of treating a tumor or a viral disease by administering a 2' , 5' -oligoadenylate analog | SANKYO COMPANY, LIMITED (JP) | 2010-02-11 | — | — | US | disclosed |
| US-7651999-B2 | phosphorothioate modification containg oligonadenylates useful as antiviral, anticarcinogenic and antitumor agent; stable and have superior activity for treating lung cancer | SANKYO COMPANY, LIMITED (JP) | 2010-01-26 | — | — | US | disclosed |
| US-20050261235-A1 | 2' ,5' -Oligoadenylate analogs | SANKYO COMPANY, LIMITED (JP) | 2005-11-24 | — | — | US | disclosed |
| EP-1568704-A1 | NOVEL 2' ,5' -OLIGOADENYLIC ACID ANALOGUES | Sankyo Company, Limited (JP) | 2005-08-31 | — | — | EP | disclosed |
| US-5986042-A | Cross-linked polymer | MITSUI CHEMICALS, INC. (JP) | 1999-11-16 | — | — | US | disclosed |
| EP-0856539-A1 | Cross-linked polymer | Mitsui Chemicals, Inc. (JP) | 1998-08-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261235-A1 | 2' ,5' -Oligoadenylate analogs | NSUN2, RNGTT, NSUN3 | DGKA 4227/4885LMNA 2237/4885TSHR 1870/4885 |
| US-20100035976-A1 | Method of treating a tumor or a viral disease by administering a 2' , 5' -oligoadenylate analog | ADAR, NSUN2, ADORA3 | DGKA 3822/4885LMNA 2298/4885TSHR 1214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.